International phase III trial of liprotamase efficacy and safety in pancreatic-insufficient cystic fibrosis patients

Abstract Background Most cystic fibrosis (CF) patients have exocrine pancreatic insufficiency (EPI) and need supplementation with pancreatic enzyme replacement therapy (PERT). Liprotamase, a novel non-porcine PERT containing highly purified biotechnology-derived lipase, protease, and amylase, has su...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of cystic fibrosis 2011-12, Vol.10 (6), p.443-452
Hauptverfasser:	Borowitz, Drucy, Stevens, Christopher, Brettman, Lee R, Campion, Marilyn, Chatfield, Barbara, Cipolli, Marco
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Amylases - adverse effects Amylases - therapeutic use Child Cystic fibrosis Cystic Fibrosis - complications Double-Blind Method Enzyme Replacement Therapy Exocrine Pancreatic Insufficiency - drug therapy Exocrine Pancreatic Insufficiency - etiology Female Humans International Cooperation Lipase - adverse effects Lipase - therapeutic use Malabsorption Male Pancreatic enzymes Pancreatic insufficiency Peptide Hydrolases - adverse effects Peptide Hydrolases - therapeutic use Pulmonary/Respiratory Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!